Azienda Sanitaria Locale Di Salerno
- Address
- Via Nizza 146, 84124 Salerno, Italy
Azienda Sanitaria Locale Di Salerno - Hematologic Malignancies and Oncology Research Center
Azienda Sanitaria Locale Di Salerno is a prominent clinical research center with extensive expertise in hematologic malignancies and oncology. The center demonstrates particular strength in investigating novel therapeutic approaches for complex blood cancers and solid tumors, with a focus on personalized medicine and targeted therapies. Their research portfolio encompasses both early-phase and late-phase clinical trials, evaluating innovative treatment combinations and immunotherapeutic strategies.
- Acute Myeloid Leukemia (AML) research, including studies on minimal residual disease (MRD), combination chemotherapy regimens, and targeted agents like venetoclax and gemtuzumab ozogamicin
- Acute Lymphoblastic Leukemia (ALL) trials focusing on Philadelphia chromosome-positive and Ph-like subtypes, utilizing tyrosine kinase inhibitors and immunotherapy combinations
- Lymphoma research across multiple subtypes including Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and MALT lymphoma with immunochemotherapy approaches
- Solid tumor investigations in renal cell carcinoma and muscle invasive bladder cancer using checkpoint inhibitors and novel immunotherapy combinations
The center actively participates in multicenter trials exploring cutting-edge treatment modalities, including checkpoint inhibitors, hematopoietic stem cell transplantation, and hypomethylating agents. Additionally, the facility conducts research in autoimmune disorders such as active proliferative lupus nephritis and psychiatric conditions including major depressive disorder, demonstrating a comprehensive approach to clinical research. Their commitment to advancing precision medicine is evident through their involvement in biomarker-driven trials and MRD-guided therapeutic strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Di Salerno
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Venetoclax and Decitabine in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasms Unfit for Intensive Chemotherapy | Fondazione Gimema Franco Mandelli Onlus | Phase II | Not Recruiting | Dec 2021 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2023-02-27 | 2023-02-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.